Advertisement
Check out our latest volumes and outcomes data
For the first time, risk is shown after accounting for underlying contributions of pulmonary disease
Undetectable levels achieved for nearly nine months in phase 1 trial
Investigators conclude that improved self-reports go beyond possible placebo effect for severe TR
Advertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Five-year data demonstrate convergence of outcomes from years 1 to 5
One-time infusion of adenovirus-based therapy is designed to restore heart muscle function
Going beyond the Eckardt symptom score to evaluate dyspepsia, eating and symptom “bother”
Randomized WATCH-TAVR trial confirms safety of the combined procedures
Study finds that in the absence of ACS, the yield is low and outcomes are unaffected
Observational study supports adding CAC score to traditional risk factors for precision medicine approach
Advertisement
Advertisement